Definitive Healthcare Corp. (NASDAQ:DH) Shares Bought by Algert Global LLC

Algert Global LLC boosted its holdings in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 21.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 282,344 shares of the company’s stock after acquiring an additional 50,700 shares during the period. Algert Global LLC owned about 0.24% of Definitive Healthcare worth $1,262,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its position in shares of Definitive Healthcare by 17.0% in the second quarter. The Manufacturers Life Insurance Company now owns 22,896 shares of the company’s stock valued at $125,000 after buying an additional 3,332 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Definitive Healthcare by 10.8% in the second quarter. Principal Financial Group Inc. now owns 39,856 shares of the company’s stock valued at $218,000 after buying an additional 3,874 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Definitive Healthcare by 31.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock valued at $116,000 after buying an additional 5,083 shares during the last quarter. Valeo Financial Advisors LLC raised its position in shares of Definitive Healthcare by 11.8% in the second quarter. Valeo Financial Advisors LLC now owns 59,080 shares of the company’s stock valued at $323,000 after buying an additional 6,230 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Definitive Healthcare by 1.9% in the second quarter. Victory Capital Management Inc. now owns 509,009 shares of the company’s stock valued at $2,779,000 after buying an additional 9,316 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DH. BTIG Research assumed coverage on shares of Definitive Healthcare in a research report on Tuesday, September 17th. They issued a “buy” rating and a $7.00 price objective for the company. Morgan Stanley dropped their price target on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a research report on Friday, November 8th. Robert W. Baird dropped their price target on shares of Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, Barclays dropped their price target on shares of Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $5.81.

Definitive Healthcare Price Performance

DH opened at $4.66 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. Definitive Healthcare Corp. has a 52-week low of $3.19 and a 52-week high of $10.62. The company has a 50 day moving average of $4.35 and a two-hundred day moving average of $4.79. The company has a market cap of $538.32 million, a P/E ratio of -1.50, a P/E/G ratio of 3.28 and a beta of 1.33.

Definitive Healthcare Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.